Browse the evidence

Semaglutide 2.4 mg/week significantly reduces the incidence of new-onset type 2 diabetes and prediabetes in overweight or obese adults without diabetes.

For overweight or obese individuals without diabetes, semaglutide 2.4 mg/week reduces the risk of developing type 2 diabetes by 73% and prediabetes by 67% compared to placebo.

Weight loss interventions, particularly pharmacologic treatments like GLP-1 receptor agonists (e.g., semaglutide, tirzepatide), significantly reduce OSA severity and may reduce cardiovascular disease risk.

If you have sleep apnea and are overweight, losing weight is one of the most powerful things you can do for your heart and your sleep. Modern medications like semaglutide or tirzepatide can help you lose significant weight, which directly reduces the severity of your sleep apnea and your risk of heart disease. Discuss these options with your doctor.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) significantly reduce major adverse cardiovascular events (MACE) and promote substantial weight loss in patients with or without diabetes, addressing core CMS components.

If you have obesity and cardiovascular risk factors, GLP-1 agonists like semaglutide or liraglutide are highly effective. They help you lose significant weight and reduce your risk of heart attacks and strokes. These are typically injected weekly or daily. Discuss with your doctor if you are a candidate, especially if you have obesity-related complications.

Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, produces substantial, sustained, and dose-dependent weight loss in adults with obesity, significantly outperforming placebo, semaglutide, and dulaglutide.

If you have obesity, Tirzepatide is a highly effective, once-weekly injection that helps you lose a significant amount of weight (up to 20% or more) by targeting the hormones that control hunger and fullness. It works better than other similar drugs and lifestyle changes alone. While it can cause temporary stomach issues like nausea, these usually get better over time. It is a long-term treatment for a chronic condition.

GLP-1 receptor agonists (Liraglutide 3.0 mg and Semaglutide 2.4 mg) produce superior weight loss and cardiovascular risk reduction compared to other pharmacotherapies, making them first-line pharmacological options for high-risk patients.

If lifestyle changes alone are insufficient, GLP-1 medications like Semaglutide or Liraglutide are the most effective pharmacological options, offering significant weight loss (up to 12+ kg) and cardiovascular benefits. They require weekly or daily injections and slow dose titration to manage side effects. Discuss cost and insurance coverage with your provider to determine if this is a viable long-term strategy.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce superior weight loss (>10% initial body weight) compared to other approved anti-obesity medications by acting centrally to increase satiety and reduce appetite.

If lifestyle changes alone haven't worked, GLP-1 agonists like semaglutide or tirzepatide are the most effective pharmacological options, capable of producing over 10% weight loss. These require weekly injections and a gradual dose titration to manage side effects like nausea.

Liraglutide and semaglutide are the only approved anti-obesity medications demonstrated to lower the risk of major cardiovascular events in patients with or without established cardiovascular disease.

For patients with obesity and existing heart disease or diabetes, Liraglutide (3mg daily) and Semaglutide (2.4mg weekly) are preferred because they reduce cardiovascular event risk, unlike other weight loss drugs.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significant weight loss in adults and adolescents with obesity by delaying gastric emptying, suppressing appetite via central satiety pathways, and stimulating glucose-dependent insulin secretion.

GLP-1 and GIP medications (like semaglutide and tirzepatide) are highly effective for weight loss, achieving 15-20% body weight reduction in clinical trials. They work by slowing digestion and reducing hunger signals in the brain. Treatment involves weekly or daily injections with gradual dose increases to minimize stomach upset. These drugs are most effective when combined with a calorie-controlled diet and regular physical activity.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces HbA1c (up to 2.6%) and body weight (up to 12.9 kg) in Type 2 Diabetes patients, outperforming existing GLP-1 agonists and insulin.

Tirzepatide is a once-weekly injectable medication for Type 2 Diabetes that works by mimicking two gut hormones (GIP and GLP-1). It is highly effective at lowering blood sugar and promoting significant weight loss, often outperforming other common diabetes medications. Patients should expect a gradual dose increase to minimize stomach upset, and pharmacists play a key role in managing side effects and ensuring adherence.

Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, produces superior weight loss and glycemic control compared to placebo, semaglutide, and insulin in patients with type 2 diabetes and obesity.

Tirzepatide is a once-weekly injection for type 2 diabetes and obesity that works by mimicking two gut hormones (GLP-1 and GIP). It is more effective than single-hormone drugs and insulin for lowering blood sugar and losing weight. Common side effects like nausea usually improve over time. It is not for type 1 diabetes or those with a history of pancreatitis.

Tirzepatide, a dual GIP/GLP-1 receptor agonist administered subcutaneously once weekly, produces significantly greater weight loss than both placebo and semaglutide in patients with type 2 diabetes and obesity.

If you have obesity or Type 2 Diabetes, tirzepatide is a highly effective weekly injection that works by mimicking gut hormones to reduce appetite and improve metabolism. It causes more weight loss than existing options like semaglutide. While it can cause stomach issues like nausea, these are usually mild and can be managed by starting with a low dose and increasing it slowly over time under medical supervision.

GLP-1 receptor agonists (GLP-1 RAs) including semaglutide, tirzepatide, and liraglutide produce significant weight loss in adults with obesity, with efficacy increasing with higher doses and outperforming placebo.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, often producing 15-20% body weight reduction in clinical trials. They work by mimicking natural hormones to reduce appetite and slow digestion. While effective, they can cause gastrointestinal side effects like nausea, which are usually manageable and temporary. Consult a doctor to determine if this treatment is appropriate for your specific health profile.

Dual GIP/GLP-1 receptor agonism (tirzepatide) provides superior glycemic control and greater weight loss compared to single GLP-1 receptor agonists (semaglutide) and insulin analogues (degludec, glargine) in patients with Type 2 Diabetes.

For patients with Type 2 Diabetes seeking maximum glucose control and weight loss, dual GIP/GLP-1 agonists like tirzepatide offer superior results compared to standard GLP-1 drugs or insulin. The treatment involves a once-weekly injection with a gradual dose escalation to manage side effects. While gastrointestinal issues like nausea are common, they are generally mild and comparable to other injectable diabetes medications.

Semaglutide (2.4 mg weekly) combined with intensive behavioral therapy produces significantly greater weight loss (16.0%) and cardiometabolic improvements compared to behavioral therapy alone (5.7%).

If you have obesity or overweight with related health issues, combining a weekly semaglutide injection (titrated to 2.4 mg) with intensive lifestyle changes (diet, exercise, counseling) can lead to substantial weight loss (around 16%) and better heart health markers compared to lifestyle changes alone. Be aware that stopping the drug may lead to weight regain, so it is intended for long-term management.

Tirzepatide (5-15 mg weekly) results in significant mean weight loss (15.0-20.9%) and improvements in waist circumference, blood pressure, and lipid levels compared to placebo.

Tirzepatide, taken as a weekly injection at doses of 5, 10, or 15 mg, can lead to 15-21% weight loss over 72 weeks, along with improvements in blood pressure and lipids, compared to placebo.

Creatine supplementation combined with resistance training significantly increases fat-free mass (FFM) and body mass in both novice and experienced lifters, with experienced lifters gaining approximately 0.6 kg more FFM than novices, though this difference is not statistically significant.

If you are lifting weights, adding creatine will help you gain more muscle and body weight than training alone. This benefit applies whether you are just starting out or have been training for years. While experienced lifters might gain slightly more muscle than beginners, the difference isn't statistically significant, meaning creatine is a valuable tool for everyone.

Long-term use of GLP-1 receptor agonists (GLP-1 RAs) provides durable cardiovascular and metabolic protection without significant long-term adverse events, whereas discontinuation leads to rapid weight regain and reversal of cardioprotective benefits.

Treat obesity as a chronic condition requiring long-term management with GLP-1 RAs. Do not stop the medication once you reach your goal weight, as you will likely regain the weight and lose cardiovascular benefits. Expect gastrointestinal side effects early on, but know they usually improve after a few months. Work with your doctor to manage costs and side effects to maintain adherence.

Once-weekly subcutaneous semaglutide (2.4 mg) resulted in a mean body weight change of -16.0% compared to -5.7% for placebo at week 68.

Semaglutide can be an effective adjunct treatment for weight management in adults with overweight or obesity.

A higher percentage of participants treated with semaglutide lost at least 5% of baseline body weight compared to placebo (86.6% vs 47.6%).

Semaglutide significantly increases the likelihood of achieving clinically meaningful weight loss.

Treatment with tirzepatide resulted in a least-squares mean percent change in weight of -20.2% at week 72, compared to -13.7% with semaglutide.

Tirzepatide may be a more effective option for weight loss in obese adults without diabetes.

Tirzepatide led to a least-squares mean change in waist circumference of -18.4 cm, while semaglutide led to -13.0 cm.

Tirzepatide may also be beneficial for reducing waist circumference in obese adults without diabetes.

Participants in the tirzepatide group were more likely to achieve weight reductions of at least 10%, 15%, 20%, and 25% compared to the semaglutide group.

Tirzepatide may provide a higher chance of achieving significant weight loss milestones in obese adults without diabetes.

Tirzepatide at doses of 5 mg, 10 mg, or 15 mg once weekly resulted in a mean percentage change in weight of -15.0%, -19.5%, and -20.9% respectively at week 72.

Tirzepatide is effective for significant weight loss in adults with obesity.

85%, 89%, and 91% of participants achieved a weight reduction of 5% or more with 5 mg, 10 mg, and 15 mg of tirzepatide respectively.

A high percentage of adults with obesity can expect significant weight loss with tirzepatide.